Pfizer Corporation

Mark A Haxell

Hiroshi Maeda

Junsuke Tone

David A Perry

Bernard Joseph Banks

Lee Richard Roberts

Graham Lunn

Michael Stephen Pacey

The invention described herein relates to: the use of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in the manufacture of a composition for the treatment of acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase to a ruminant; a formulation suitable for the treatment of acidosis in an animal which comprises an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase; a compound of the formula I: or veterinarily acceptable salt, solvate (including hydrate) or prodrug thereof; and processes to make an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase useful for the treatment of acidosis in a ruminant.

Treatment of rumen acidosis with &#x3b1;-amylase inhibitors

The invention described herein relates to: the use of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in the manufacture of a composition for the treatment of rumen acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase to a ruminant; a formulation suitable for the treatment of rumen acidosis in an animal which comprises an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase; a compound of the formula I:or veterinarily acceptable salt, solvate (including hydrate) or prodrug thereof; and processes to make an effective inhibitor of a bacterial &#x3b1;-amylase and/or &#x3b1;-glucosidase useful for the treatment of acidosis in a ruminant.

The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pests, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions comprising such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Process for producing antiparasitic macrolide antibiotics

The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pests, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions containing such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Biologically pure culture of Streptomyces hygroscopicus ATCC 53718

The present invention relates to certain antibiotic compounds, designated N787-182 compounds herein and derivatives thereof, which are antiparasitic agents, active against insect pest, acari, free-living nematodes and endo- and ectoparasites. This invention also relates to pharmaceutical and other compositions comprising such compounds, methods of using such compounds, the microorganism Streptomyces hygroscopicus ATCC 53718 and mutants or genetically transformed or recombinant form thereof, and processes for producing such compounds.

Growing community of inventors

Broadstairs, United Kingdom

Mark A Haxell